Psychiatry - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/232

Filters

2021 2
Reset filters

Settings
Statistics
Citations
Start date: 2021 × End date: 2021 × Author: Sarris, Jerome × Author: Perkins, Daniel × Type: Journal Article ×

Search Results

Now showing 1 - 2 of 2
  • Item
    No Preview Available
    Legalization of Psychedelic Substances
    Downey, LA ; Sarris, J ; Perkins, D (AMER MEDICAL ASSOC, 2021-12-21)
  • Item
    Thumbnail Image
    Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
    Galvao-Coelho, NL ; Marx, W ; Gonzalez, M ; Sinclair, J ; de Manincor, M ; Perkins, D ; Sarris, J (SPRINGER, 2021-02)
    RATIONALE: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option. OBJECTIVE: We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo for mood state and symptoms of depression in both healthy and clinical populations (separately). RESULTS: Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1). The meta-analyses of acute mood outcomes (3 h to 1 day after treatment) for healthy volunteers and patients revealed improvements with moderate significant effect sizes in favor of psychedelics, as well as for the longer-term (16 to 60 days after treatments) mood state of patients. For patients with mood disorder, significant effect sizes were detected on the acute, medium (2-7 days after treatment), and longer-term outcomes favoring psychedelics on the reduction of depressive symptoms. CONCLUSION: Despite the concerns over unblinding and expectancy, the strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms.